MSK’s phone number for new patient appointments is currently down. Until the issue is resolved, you can contact us through our online appointment form. We apologize for the inconvenience. Read more

More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

MSK-PCa3: Human Prostate Cancer Organoids

Description

The organoids from the biopsy showed a similar mucinous histology that was diffusely positive for AR and pan-cytokeratin. When grafted into mice, the tumor exhibited the identical histology as well as positivity for AR and pan-cytokeratin. The established organoid line exhibits a double time of 1 week.

Source

MSK-PCa3 is derived from a patient who presented with metastatic prostate cancer to the pelvic lymph nodes with a diagnosis PSA of only 1.53 ng/dl. Biopsy showed adenocarcinoma with mucinous features that was positive for AR but negative for PSA. Despite a PSA response to <0.05 ng/dl, the patient progressed radiographically and a second biopsy was performed.

Inventors

  • Yu Chen, MD, PhD,  Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center
  • Dong Gao, PhD, formerly at Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center

Key References

Gao D, et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell,  2014;159(1):176-87.

Licensing Information

This organoid cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

For licensing requests: Alexandra Buga, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org.

Stage of Development

Ready to use

Indications